Table Of Content
- Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
- Barchart Technical Opinion
- Design Therapeutics stock plunges on trial results for neuromuscular disease treatment
- Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. Design Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off last year's report dates. While Design Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys. Design Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BML Capital Management LLC (1.56%), Assenagon Asset Management S.A. (0.62%) and Simplicity Wealth LLC (0.02%).
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
And you know, I think a couple of things we're right now in this very acute stage where these compounds have just been recently approved for weight loss and there is just overwhelming demand and the supply isn't quite there. We don't consider that to be a terminal state. We do see from the existing companies in the space, it ramp up in manufacturing capacity. We know on the contractor side, there is a massive attention being paid paid to this this issue. And so I think the supply dynamics will probably evolve over the next few years, still going to be a difficult challenge, but I think we're not in a permanent shortage state, we don't think. So with the translatability for liver fat to histologic improvement.
Barchart Technical Opinion
After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. Even if one or more of Design Therapeutics’ treatments is fully accepted by regulators, this doesn’t necessarily mean the company will succeed on a financial level. Design Therapeutics has been unprofitable, quarter after quarter.
Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition - Yahoo Finance
Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition.
Posted: Wed, 08 Mar 2023 08:00:00 GMT [source]
Design Therapeutics stock plunges on trial results for neuromuscular disease treatment
And maybe there is a backlog of people waiting to trial and a backlog of clinicians waiting to do I prescribe It's so unknown right now, it's hard to hard to project, but it is true that the GLP ones are getting more and more utilization. And there's a middle question in there, I think I skipped. Hello and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO, and Greg Zante, Viking's CFO.
Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results
Design Therapeutics, Inc. has a 12 month low of $1.94 and a 12 month high of $8.47. The firm's fifty day simple moving average is $3.25 and its 200-day simple moving average is $2.66. Design Therapeutics has a widening net earnings loss and a declining liquidity position. Also, there’s no guarantee that the FDA will fully approve the company’s clinical programs. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud.
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California. About Design TherapeuticsDesign Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease.
These issues can, to a large extent, be attributed to Design Therapeutics’ spending. The company’s operating expenses grew dramatically from 2021 to 2022. Moreover, there’s no mention of cost reduction in Design Therapeutics’ most recently published earnings press release.
And I'll now turn the call over to Brian Lian for his initial comments. Xaira is building significant AI research capabilities spanning fundamental computational methods development and their application to biological discovery, the design of drug-like matter, and clinical development. Xaira was co-founded by Dr. David Baker, Professor of Biochemistry and Director of the Institute for Protein Design at the University of Washington School of Medicine. The company now employs a group of researchers who developed the leading models for protein and antibody design, RFdiffusion and RFantibody, while in Dr. Baker’s lab. Xaira’s broader team will advance these models and develop new methods that can connect the world of biological targets and engineered molecules to the human experience of disease. And I think we'll have to see what the data look like, but we'll be probably looking for a partner with the program, but hard to say without having a look at the data first.
Design Therapeutics Earnings History by Quarter
They don't really have abnormalities of very long-chain fatty acids, but we did see some reductions in very long-chain fatty acids in that prior Phase one experience. So if we can see somewhere in the mid to high 10s on the very long-chain fatty acid reduction that would be a pretty interesting, hopefully more than that. But that would be probably that the gating factor to consider further development in X-linked adrenoleukodystrophy.
On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 45.5% from the stock's current price. View analysts price targets for DSGN or view top-rated stocks among Wall Street analysts. With respect to what would be available and when will that those are the primary components of the data that we'll receive. We will be receiving probably little later data on paired biopsy reads, you know, what is someone's NASH, better, unchanged or worse at the end of the treatment period that that kind of thing since those take a little bit longer to evaluate. So we'll we haven't received the final data from the study.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. Gain deeper insights into company revenues with a detailed analysis of revenue sources. Explore the updated Options feature, providing in-depth data, and a 3D viewing option.
Design Therapeutics has generated ($1.20) earnings per share over the last year (($1.20) diluted earnings per share). Earnings for Design Therapeutics are expected to decrease in the coming year, from ($1.26) to ($1.46) per share. Design Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off prior year's report dates. 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last year. There are currently 7 hold ratings for the stock.
This study demonstrated encouraging safety and tolerability as well as promising weight loss following 28 days of once daily dosing. The Company plans to advance both of both of these programs into further development later this year. In addition, during the first quarter, the Company completed the final biopsies in the Phase IIb VOYAGE study evaluating the novel thyroid hormone receptor beta agonist VK. Two eight oh nine in patients with NASH and fibrosis. We expect to report the biopsy results from this study later this quarter.
No comments:
Post a Comment